Overview of pulmonary arterial hypertension in children, complications, and management

Nawal Abdullah Awdah Abdullah, Maha Saeed Nasser Alobaid

Abstract:

This review of pulmonary arterial hypertension will highlight the key features of pulmonary hypertension in children and the current understanding of pulmonary arterial hypertension with management methods. We performed a comprehensive search using electronic databases; MEDLINE, EMBASE, and google scholar, through October, 2017. Search strategies used following MeSH terms in searching via these databases: “pulmonary arterial hypertension”, “pediatrics”, “children”, “complications”, “management”, “treatment”. Pulmonary arterial hypertension is a serious dynamic condition with a poor prognosis if not identified and managed early. Because the signs are nonspecific and the physical findings can be subtle, the illness is often recognized in its later stages. Pulmonary arterial hypertension (PAH) is a dangerous illness whose prognosis has altered significantly over the past years because the introduction of new therapeutic agents in addition to the off-label application of grown-up pulmonary hypertension specific treatments to kids. Therapy in adults is proof based on randomized, placebo-controlled trials. However, therapy in children is based on experience. Future clinical trials must take into consideration the special aspects of PAH in children, including pharmacokinetics, clinical endpoints, and long-term toxicity.

Introduction:

Pulmonary arterial hypertension (PAH) is defined as a mean pulmonary arterial blood pressure that exceeds 25 mmHg at rest or 30 mmHg throughout exercise in association with variable levels of lung vascular remodeling, vasoconstriction, and in situ thrombosis [1].Kids with PAH commonly have an enhanced requirement for clinical resources and may get numerous general anesthetics for procedures connected to PAH analysis and management. The pathophysiology of PAH (4-6) and the connected anesthetic factors to consider for adults and kids have been evaluated [2].PAH contributes to perioperative morbidity and death [3].

Up until just recently the diagnosis of primary lung hypertension was basically a death penalty. This was specifically true for children, in whom the mean survival was <1 year. This bleaker outlook for children compared with grownups was underscored by the information in the Primary Pulmonary Hypertension National Institutes of Health Registry [1].In this Registry, the average survival for all of the 194 patients was 2.8 years, whereas it was only 10 months for youngsters. Considerable progression in the field of lung hypertension has taken place over the past numerous decades. Advancements in technology have likewise enabled a much better diagnosis and evaluation of the disease extent with treatment currently available that enhances quality of life and survival [4].Nonetheless, extrapolation from grownups to youngsters is not simple for a

minimum of numerous factors: 1) the anticipated lifespan of kids is longer; 2) kids might have a better reactive pulmonary blood circulation elevating the prospect of greater vasodilator responsiveness and better therapeutic end results [5]; and 3) despite medical and pathological studies recommending boosted vasoreactivity in youngsters, prior to the development of long-term vasodilator/antiproliferative treatment, the nature stayed significantly worse for kids compared with grown-up patients [6].

This review of pulmonary arterial hypertension will highlight the key features of pulmonary hypertension in children and the current understanding of pulmonary arterial hypertension with management methods.

Methodology:

We performed a comprehensive search using electronic databases; MEDLINE, EMBASE, and google scholar, through October, 2017. Search strategies used following MeSH terms in searching via these databases: “pulmonary arterial hypertension”, “pediatrics”, “children”, “complications”, “management”, “treatment”. Then we also searched the bibliographies of included studies for further relevant references to our review. Restriction to only English published study with human subject.

Discussion:

- **Definition and Classification**

PAH is specified as a mean pulmonary artery pressure (PAP) ≥ 25 mmHg at rest, with a regular pulmonary capillary wedge pressure (≤ 15 mmHg) and increased pulmonary vascular resistance index (≥ 3 Wood units x m2) [7]. Categorizing pediatric PH inning accordance with the WHO classification (Table 1) is bothersome as several children with PH have linked co-morbidities and disorders [8].A functioning team of the Pulmonary Vascular Research Institute developed a classification certain to children [9].Particularly, this classification identified the ideas of the payment of abnormalities of lung growth and development to pediatric PH. PH can create in utero or can be superimposed on key durations of lung advancement resulting in life-long airway and pulmonary vascular irregularities. Pediatric pulmonary hypertensive vascular illness has been split right into 10 broad categories. Several kids presenting with PH have heterogeneous illness consisting of differing inclining variables, consisting of prematurity, a chromosomal or genetic anomaly, congenital heart disease, and rest disordered breathing. PH connected with bronchopulmonary dysplasia has been highlighted in this classification. For youngsters with a biventricular blood circulation, the interpretation resembles adults; nevertheless, the Panama classification specifically includes kids with PH in the setup of solitary ventricle physiology after a cavopulmonary anastomosis. In this setup, pediatric pulmonary hypertensive vascular disease is defined as a pulmonary vascular resistance index > 3.0.Wood units X m2 or a transpulmonary gradient > 6 mmHg [9].This classification was not created to figure out use targeted PH therapy however instead a help in classification and assessment of kids with PH.

Table 1. Classification of pulmonary arterial hypertension [10].

1. Idiopathic PAH (IPAH)
2. Heritable
1.BMPR2
2.ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia)
3.Unknown
3. Drug and toxin-induced
4.Associated with (APAH)
1.Connective tissue diseases
2.HIV infection
3.Portal hypertension
4.Congenital heart diseases
5.Schistosomiasis
6.Chronic hemolytic anemia
5. Persistent pulmonary hypertension of the newborn

Table2. The broad schema of 10 basic categories of Pediatric Pulmonary Hypertensive Vascular Disease [11].

1. Prenatal or developmental pulmonary hypertensive vascular disease
2. Perinatal pulmonary vascular maladaptation
3. Pediatric cardiovascular disease
4. Bronchopulmonary dysplasia
5. Isolated pediatric pulmonary hypertensive vascular disease (isolated pediatric PAH)
6. Multifactorial pulmonary vascular disease in congenital malformation syndromes
7. Pediatric lung disease
8. Pediatric thromboembolic disease
9. Pediatric hypobaric hypoxic exposure
10. Pulmonary vascular disease associated with other system disorders

- **Epidemiology**

The frequency of pulmonary arterial hypertension in youngsters in addition to in grownups continues to be unknown. Estimations of the occurrence of primary pulmonary hypertension varieties from one to two new instances each million individuals in the basic population [12].Although the condition is uncommon, progressively constant records of confirmed instances recommend that even more patients (both kids and adults) have lung arterial hypertension compared to had actually been formerly acknowledged. From time to time, babies that have passed away with the assumed medical diagnosis of sudden infant death syndrome have had primary pulmonary hypertension identified at the time of post-mortem examination. The sex incidence in grown-up patients with primary pulmonary hypertension is ~ 1.7:1 women: men [13], just like the current authors' experience with children, 1.8:1 without substantial difference in the younger youngsters compared to the older kids.

- **Diagnostic evaluation**

As one of the most effective strategy in the treatment of pulmonary hypertension is to treat the underlying reason, the workup of lung hypertension involves a full background and exam (box 2) and comprehensive assessment (Table 3), intending to exclude all known aetiologies of lung hypertension (Table 4). Idiopathic pulmonary arterial hypertension is specified as a diagnosis of exclusion [14]. The history and health examination must be carried out with attention to aetiology (Table 3). Symptoms could include exertional dyspnoea, decreasing exercise tolerance, orthopnoea, atypical chest pain, and haemoptysis. Syncope in this problem is a worrying sign of end phase disease.

Table 3. History and examination

History
Diet pill use; contraceptive pill; methamphetamine use
Onset and length of pulmonary hypertension
Family history of pulmonary hypertension
Prior cardiac and other surgeries
Symptoms
Chest pain; dyspnoea; shortness of breath; syncope
Physical examination
Loud second heart sound; systolic murmur of tricuspid regurgitation or diastolic murmur of pulmonary insufficiency; palpable second heart sound; peripheral oedema; jugular venous distension

Non-invasive diagnostic studies are important in the examination of pulmonary hypertension (box 2). Cardiac catheterisation is necessary to evaluate pulmonary artery pressure and resistance in addition to establish reactivity of the pulmonary vasculature. Additionally, as breathing illness is an important cause of pulmonary hypertension, extensive analysis of the lung must be undertaken (Table 4).

Table 4: Diagnostic evaluation of pulmonary hypertension

• Chest radiograph (signs of cardiomegaly and enlarged pulmonary arteries) • ECG (right ventricular hypertrophy and ST-T changes) • Echocardiogram • Cardiac catheterisation with acute vasodilator testing • Complete blood count, urinalysis • Hypercoagulable evaluation	• Collagen vascular workup—looking for autoimmune disease • Lung evaluation • Six minute walk test/cycle ergometry • HIV test • Liver evaluation • Thyroid function tests • Toxicology screen (cocaine/methamphetamine and HIV testing)

- **Connection between disease and complications**

Congenital heart disease

A selection of congenital cardiac lesions create pulmonary hypertension (Table 5). The age at which these lesions trigger irreparable pulmonary vascular illness varies. In general, patients with ventricular septal flaw or patent ductus arteriosus do not create irreversible pulmonary vascular adjustments before 1 year old. Children with Down's syndrome could have an increased danger of pulmonary hypertension. Moreover, babies with an atrial septal defect or ventricular septal defect with chronic lung disease have an increased risk for the early growth of extreme pulmonary vascular illness. Patients with atrioventricular septal problem may establish irreversible lung vascular condition earlier compared to patients with other left-to-right shunt lesions.

Table 5. cardiac lesions associated with pulmonary hypertension

• Left-to-right shunts	• Cyanotic heart disease
– Ventricular septal defect	– Transposition of the great arteries
– Atrioventricular septal (canal) defect	– Truncus arteriosus
– Patent ductus arteriosus	– Tetralogy of Fallot (pulmonary atresia/VSD)
– Atrial septal defect	– Univentricular heart (high-flow with/without restrictive atrial septum)
– Aorto-pulmonary window	• Anomalies of the pulmonary artery or pulmonary vein
• Increased pulmonary venous pressure	– Origin of a pulmonary artery from the aorta
– Cardiomyopathy	– Unilateral “absence” of a pulmonary artery
– Coarctation of the aorta (left ventricular diastolic dysfunction)	– Scimitar syndrome
– Hypoplastic left heart syndrome	• Palliative shunting operations
– Shone complex	– Waterston anastamosis
– Mitral stenosis	– Potts anastamosis
– Supravalvar mitral ring	– Blalock-Taussig anastamosis

– Cor triatriatum – Pulmonary vein stenosis/veno-occlusive disease – Total anomalous pulmonary venous return	

Patients with cyanotic congenital cardiac lesions might also create pulmonary hypertension. Hypoxaemia with boosted shunting is a powerful stimulus for the fast development of pulmonary vascular disease. Examples include transposition of the excellent arteries, truncus arteriosus, and univentricular heart with high flow. Total improvement of many cardiac lesions in the first months of life may prevent the late development of pulmonary hypertension. Ultimately, palliative shunting procedures for certain cardiac anomalies developed to boost pulmonary blood flow might result in the advancement of pulmonary hypertension.

Thromboembolic disease

Thromboembolic disease as a reason for pulmonary hypertension in kids is unusual. Nonetheless, a precise diagnosis is crucial for therapy [15].Predisposing aspects consist of collagen vascular disease, hypercoagulation disorders (see box 1), bacterial endocarditis, in addition to a best atrial shunt (cerebral ventricular) for hydrocephalus. Similarly, using oral contraceptive agents might trigger hypercoagulation causing pulmonary thromboembolic phenomena. Medical diagnosis entails a high index of uncertainty, as well as examination by ventilation perfusion scanning and CT scanning. In adults with chronic thromboembolic pulmonary hypertension, lung thromboendarterectomy has been shown to boost survival and lifestyle.

Eisenmenger syndrome

Eisenmenger syndrome describes lung hypertension with a reversed main shunt [14].In general, the term "Eisenmenger syndrome" is made use of for shunts distal to the tricuspid valve. Enhanced pulmonary vascular resistance, and bidirectional or right-to-left shunting via a systemic-to-pulmonary link, such as a ventricular septal issue, patent ductus arteriosus, univentricular heart, or aortopulmonary window characterises this disorder. The shunt is originally left-to-right, however as the underlying condition continues to increase pulmonary vascular resistance, there is a turnaround of the shunt, resulting in cyanosis, and erythrocytosis. Generally, the diagnosis of patients with Eisenmenger disorder is far better than for patients with idiopathic lung arterial hypertension. Syncope, best heart failure, and serious hypoxemia have been related to a poor prognosis. Phlebotomy may be used in Eisenmenger syndrome and need to be reserved for momentary alleviation of significant hyperviscosity symptoms or to improve perioperative haemostasis. Non-cardiac operations on Eisenmenger patients are connected with a high death rate, and should be managed by a multidisciplinary group experienced in the care of patients with pulmonary hypertension.

- **Treatment of pulmonary arterial hypertension**

Immunisation timetables must be maintained, and young children need respiratory syncytial infection prophylaxis with palivizumab. Anaesthesia for any type of general medical or dental treatment needs particular care.

The objective of medical treatment is to expand the pulmonary vasculature and turn around the irregular renovation characteristic of pulmonary vascular condition. The sensible difficulties come across in treating youngsters influence management and include their age, level of understanding, size and in some, the presence of other abnormalities. 3 signalling pathways are targeted: the prostacyclin, endothelin and nitric oxide paths.

Prostacyclin and its analogues

One of the most reliable therapy is a constant intravenous mixture of epoprostenol, the sodium salt of prostacyclin. It has a short half-life of 3- 5 minutes, is unstable and the infusion has to be prepared every 24 h. The concept side effects are jaw discomfort and diarrhoea. The kid is dosed according to reaction. Children need a lot greater doses than grownups. A more steady analogue of prostacyclin, treprostinil, can also be provided intravenously but is connected with more prominent adverse effects, headaches and leg discomfort. Precise care of the Hickman line is necessary to protect against regional and systemic infections, the last being incredibly unusual. Treprostinil can likewise be provided by constant subcutaneous mixture yet hurts, the medication stimulating nerve endings and creating induration and in some cases ulceration of the skin [16].It is not made use of in children. Iloprost is a prostacyclin analogue which can be offered by inhalation however small, tired youngsters discover it difficult to inhale an effective dose every 2 h. The medicine works for less than 2 h.

Endothelin receptor antagonists

The dual endothelin (ET) receptor antagonist bosentan (Tracleer) was the first oral medication revealed to be efficacious in IPAH and has been made use of thoroughly in this and various other sorts of pulmonary hypertension because its intro in 2002 [17]. It is efficacious in kids [18].Its principle negative effects is altitude of liver enzymes which demands a month-to-month blood examination. Drug interactions could occur. Bosentan decreases efficient direct exposure to warfarin due to induction of CYP3A4 and/or CYP2C9. The more recent careful ET-A receptor antagonists, sitaxentan and ambrisentan have not yet been studied in youngsters. Both medicines impact the liver less than bosentan and medication communication is most likely less likely with ambrisentan.

Phosphodiesterase inhibitors

Sildenafil was the very first drug of this class and is still one of the most frequently made use of, particularly in children with APAH. The concept side effects include erections and systemic hypotension when high doses are used. The dosage is 0.5-- 1 mg/kg/dose, given three to 4 times a day, seldom more.

Anticoagulation

Patients with pulmonary vascular illness are prone to develop thrombosis in situ. Older kids are offered warfarin and more youthful ones typically receive aspirin. The INR must be checked specifically carefully in those on endothelin receptor antagonists.

Oxygen

Oxygen is a powerful pulmonary vasodilator. Nocturnal supplementary oxygen is suggested if there is nighttime systemic arterial oxygen desaturation and can benefit those with a high PAP.

Atrial septostomy

This procedure is suggested in youngsters with IPAH and post-operative pulmonary hypertension suffering from syncope and/or extreme appropriate heart failure [19].It minimizes the result of an abrupt boost in pulmonary arterial and best heart pressures and keeps a left ventricular output [20].

Lung and heart–lung transplantation

The policy of the UK Pulmonary Hypertension Service is to refer kids on intravenous epoprostenol for evaluation by the transplantation service when they are developed on treatment and are still well [21].They are after that assessed by the transplantation service as suggested. Cystic fibrosis represents the majority of lung transplants, with primary pulmonary hypertension as an indication for transplantation in 14-17% of patients [22]. For certain patients, including those with congenital heart disease, heart-lung transplantation could be essential.

Conclusion:

Diagnosis and therapy of children with pulmonary arterial hypertension (PAH) lags behind the understanding and treatment of this disorder in adults. Although advances in therapy have resulted in enhanced survival for many types of PAH, there remains no cure for some, involving Idiopathic PAH (IPAH). Pulmonary arterial hypertension is a serious dynamic condition with a poor prognosis if not identified and managed early. Because the signs are nonspecific and the physical findings can be subtle, the illness is often recognized in its later stages. Pulmonary arterial hypertension (PAH) is a dangerous illness whose prognosis has altered significantly over the past years because the introduction of new therapeutic agents in addition to the off-label application of grown-up pulmonary hypertension specific treatments to kids. Therapy in adults is proof based on randomized, placebo-controlled trials. However, therapy in children is based on experience. Future clinical trials must take into consideration the special aspects of PAH in children, including pharmacokinetics, clinical endpoints, and long-term toxicity.

Reference:

1. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343–349.
2. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76–81.
3. Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984;1:1046–1047.
4. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409–415.

5. Yamaki S, Wagenvoort CA. Comparison of primary plexogenic arteriopathy in adults and children. A morphometric study in 40 patients. Br Heart J 1985;54:428–434.
6. Sandoval J, Bauerle O, Gomez A, Palomar A, Martinez Guerra ML, Furuya ME. Primary pulmonary hypertension in children: clinical characterization and survival. J Am Coll Cardiol 1995;25:466–474.
7. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S43–54.
8. van Loon RL, Roofthooft MT, van Osch-Gevers M, Delhaas T, Strengers JL, Blom NA, et al. Clinical characterization of pediatric pulmonary hypertension: complex presentation and diagnosis. J Pediatr. 2009 Aug;155(2):176–82. e1.
9. Cerro MJ, Abman S, Diaz G, Freudenthal AH, Freudenthal F, Harikrishnan S, et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ. 2011;1(2):286–98.
10. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(suppl 1):S43-S54.
11. Cerro MJ, Abman S, Diaz G, Freudenthal AH, Freudenthal F, Harikrishnan S, et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ. 2011;1(2):286-98.
12. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111–117.
13. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216–223.
14. Berman EB, Barst RJ. Eisenmenger's syndrome: current management. Prog Cardiovasc Dis2002;45:129–38.
15. Auger WR, Channick RN, Kerr KM, et al. Evaluation of patients with suspected chronic thromboembolic pulmonary hypertension. Semin Thorac Cardiovasc Surg1999;11:179–90.
16. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165(6):800–4.
17. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346(12):896–903 .
18. Maiya S, Hislop AA, Flynn Y, et al. Response to bosentan in children with pulmonary hypertension.Heart 2006;92(5):664–70 .
19. Micheletti A, Hislop AA, Lammers A, et al. Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension. Heart 2006;92(7):969–72.
20. Sandoval J , Gaspar J, Pulido T, et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol1998;32:297–304.

21. Sandoval J , Gaspar J, Pulido T, et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol1998;32:297–304.
22. Gaynor JW, Bridges ND, Clark BJ, et al. Update on lung transplantation in children. Curr Opin Pediatr1998;10:256–61.